Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 35 Glioblastoma 24 Carcinoma, Non-Small-Cell Lung 21 Ovarian Neoplasms 14 Carcinoma, Hepatocellular 14 Brain Neoplasms 14 Carcinoma, Renal Cell 13 Pancreatic Neoplasms 12 Neoplasms 10 Neoplasm Metastasis 10 Glioma 10 Breast Neoplasms 10 Colonic Neoplasms 8 Astrocytoma 8 Melanoma 7 Uterine Cervical Neoplasms 6 Rectal Neoplasms 6 Liver Neoplasms 6 Gliosarcoma 6 Endometrial Neoplasms 6 Stomach Neoplasms 5 Lung Neoplasms 5 Fallopian Tube Neoplasms 5 Colorectal Cancer Metastatic 5 Advanced Solid Tumors 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Oligodendroglioma 4 Triple Negative Breast Neoplasms 3 Small Cell Lung Carcinoma 3

Interventions

pembrolizumab 2 Paclitaxel 2 Carboplatin 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Lenalidomide 1 Interferon alpha-2 1 Gemcitabine 1 Cisplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Recurrent × Bevacizumab × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡